Listen to this article

Sanofi plans to boost its U.S.-based research and development and manufacturing investments to at least $20 billon over the next five years.

In a May 14 press release, the French multinational pharmaceutical said it expects to grow its U.S. manufacturing footprint through direct investments in sites it already owns, as well as via partnerships with other domestic drugmakers, to ensure production of medicines in America.

The strategy also calls for a “substantial” increase in R&D spending to “accelerate” science, said Sanofi. The company also noted that it is preparing for the “potential launch of numerous first- or best-in-class medicines across many indications in the coming years.”

The pharma – which recently relocated its U.S. headquarters from Bridgewater to Morristown – said its plan will create jobs and spark innovation, as well as enhance the U.S. supply chain.

“While Sanofi‘s investment decisions will be adjusted as the external environment continues to evolve, the planned investments are expected to create a significant number of high-paying jobs in multiple states in the coming years,” the company said.

In a statement, the company’s chief executive officer, Paul Hudson, said, “Sanofi’s 13,000 US-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas. Our expected investments in the U.S. will be substantial and will help ensure the production of key medicines in the U.S.”

Trending

Sanofi joins a growing number of New Jersey pharma giants that recently announced multiyear investments aimed at boosting their U.S. manufacturing footprints amid renewed threats of import tariffs on pharmaceuticals from the Trump administration.

New Brunswick-based Johnson & Johnson promised to spend more than $55 billion, while Rahway-headquartered Merck & Co. pledged $8 billion domestically by 2028 and Novartis in East Hanover expects to allocate $23 billion.

Though President Donald Trump’s sweeping tariff announcement last month excluded the industry, he has repeatedly threatened sector-specific duties and cited drugmakers’ reliance on production sites around the world to supply the U.S. market.